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Abstract
Background: HIV-infected women are at increased risk for developing cervical cancer. Women living in resource-limited
countries are especially at risk due to poor access to cervical cancer screening and treatment. We evaluated three cervical
cancer screening methods to detect cervical intraepithelial neoplasia grade 2 and above (CIN 2+) in HIV-infected women in
South Africa; Pap smear, visual inspection with 5% acetic acid (VIA) and human papillomavirus detection (HPV).
Methods: HIV-infected women aged 18–65 were recruited in Johannesburg. A cross-sectional study evaluating three
screening methods for the detection of the histologically-defined gold standard CIN-2 + was performed. Women were
screened for cervical abnormalities with the Digene HC2 assay (HPV), Pap smear and VIA. VIA was performed by clinic
nurses, digital photographs taken and then later reviewed by specialist physicians. The sensitivity, specificity and predictive
valves for CIN-2 + were calculated using maximum likelihood estimators.
Results: 1,202 HIV-infected women participated, with a median age of 38 years and CD4 counts of 394 cells/mm3. One third
of women had a high grade lesion on cytology. VIA and HPV were positive in 45% and 61% of women respectively.
Estimated sensitivity/specificity for HPV, Pap smear and VIA for CIN 2+ was 92%/51.4%, 75.8%/83.4% and 65.4/68.5% (nurse
reading), respectively. Sensitivities were similar, and specificities appeared significantly lower for the HPV test, cytology and
VIA among women with CD4 counts #200 cells/mm3 as compared to CD4 counts .350 cells/mm3.
Conclusions: Although HPV was the most sensitive screening method for detecting CIN 2+, it was less specific than
conventional cytology and VIA with digital imaging review. Screening programs may need to be individualized in context of
the resources and capacity in each area.
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Introduction
Invasive cervical cancer is the third most common cancer
among women worldwide [1], with significantly higher incidence
rates among HIV-infected than HIV-negative women [2].
Among HIV-infected women, there are no standard guidelines
on the optimal methods to screen and treat for cervical cancer in
resource-limited countries (RLC). Access to screening in RLC is
limited due to financial and personal capacities. The implemen-
tation of a cervical cancer screening program with technically
appropriate detection methods could reduce morbidity and
mortality among HIV-infected women. While alternative screen-
ing methods have been evaluated for the detection of high-grade
cervical intra-epithelial neoplasia (CIN 2/3) in Africa [3–5]; a
systematic comparison of the three most common cervical cancer
screening methods (Pap smear; visual Inspection of the cervix with
3–5% acetic acid (VIA); and HPV DNA testing) has not been
conducted in HIV-infected women in Africa. In addition, none of
these studies of HIV-infected women evaluated the performance of
the three screening methods stratified by levels of CD4 counts in
order to determine if accuracy of these tests vary by immune
status.
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e53494
To determine optimal cervical cancer screening approaches for
HIV-infected women, we aimed to compare the sensitivity and
specificity of conventional Pap smear screening to that of HPV
DNA and VIA testing for the detection of histologically confirmed
high-grade cervical neoplasia grade 2 and above (CIN 2+) in 1,202
HIV infected women from Johannesburg, South Africa. We
present results of the largest screening study in HIV positive
women to date to determine the clinical performance of these
three screening methods.
Methods
Ethics and Other Approvals
The protocol was reviewed and approved by the Human Ethics
Committee (Medical) of the University of the Witwatersrand and,
for secondary data analyses, by the University of North Carolina.
Study Population and enrolment
A total of 1,202 HIV-infected women (18–65 years of age) were
recruited from an HIV treatment clinic located in a tertiary
government hospital in Johannesburg South Africa. Women were
ineligible to participate if they (i) were pregnant, (ii) had previously
undergone a hysterectomy or treatment for cervical neoplasia or
cancer, iii) were severely ill, or (iv) had signs and/or symptoms
suggestive of a sexually transmitted disease (STD). Women were
study-eligible following the treatment of any symptomatic STD.
Women who were menstruating at study enrollment were asked to
return within one to two weeks to participate.
After an educational session was presented on cervical cancer
screening in English or Zulu/Sesotho, health workers screened
potential eligible women for exclusion criteria, explained study
aims, and obtained written informed consent. A medical history
was obtained through participant interviews to obtain information
on socio-demographic characteristics, antiretroviral therapy status,
and other lifestyle factors, including smoking and snuff (traditional
chewing tobacco) use, reproductive/menstrual characteristics,
sexual history and history of contraceptive use.
Study related procedures
Each woman was screened for this cross-sectional study using
three different methods: i) HPV DNA test (QIAGEN Hybrid
Capture 2: HC2), ii) conventional Pap smear cytology, and iii)
VIA. During a pelvic examination, the HPV sampling was first
conducted using a Digene Cervical Sampler Hybrid Capture-2
(HC-2) brush and placed in standard transport media (STM)
(QIAGEN Corporation). HPV DNA laboratory testing was
conducted at the University of Cape Town using the Digene
Hybird Capture-2 (HC-2) method (QIAGEN), and the HPV
laboratory team was blinded to other study results. HPV DNA test
results were not used for clinical management.
For a conventional Pap smear diagnosis, cervical exfoliated cells
were then collected using a Papette Cervical Cell Collector
(Wallach Surgical Devices) and smeared onto cytology slides which
were read and analyzed according to Bethesda 2001 guidelines
[6]. Women were referred to immediate colposcopy if they had
any abnormal cytology diagnosis, including high grade squamous
intra-epithelial lesions (HSIL), atypical squamous cells cannot
exclude high grade lesion (ASC-H), low grade squamous intra-
epithelial lesions (LSIL) and atypical squamous cells of under-
determined significance (ASCUS). To adjust for verification bias
[7], twenty-five percent of all women with negative Pap smears
and negative VIA were randomly referred for colposcopic biopsy
at 12 and 6 locations on the cervix. All cytology smears were
analyzed at the National Health Laboratory Services cytology
unit.
After Pap smear sampling, VIA was preformed, by applying 5%
acetic acid to the cervix followed by a three minute waiting period.
Nurses were previously trained at a two week course in Lusaka,
Zambia [8]. Visualization of the cervix was conducted and an
electronic photographic record was taken using a digital camera.
These digital images were used for quality assurance for review by
the study specialist physicians. VIA was initially interpreted by the
study nurse, and classified as per International Agency for
Research on Cancer guidelines (IARC/World Health Organiza-
tion (WHO)). A VIA was considered positive with the presence of
acetowhite lesions, if there were distinct white lesions on the cervix
within or close to the transformation zone, covering the cervix, or
on a cervical growth [9]. All women with a positive VIA result
were referred to colposcopy. During colposcopy, a colposcopic
directed biopsy was taken for histological confirmation by an
anatomical pathologist. The study cytopathologist and anatomical
pathologist were blinded to the VIA, HPV and other study results.
Quality Assurance
The cytology unit and the Anatomical Pathology Department
are accredited by the South African National Accreditation
System (SANAS) and undergo regular proficiency testing by the
Royal College of Pathologist of Australasia Quality Assurance
Programme (RCPA). Internally there is 100% second on minute
review by another cytotechnologist of all negative Pap smears and
senior cytotechnologist/pathologist review all positive (ASCUS+)
cases. Also a there is a cytological/histology review process. Study
cytology readings have previously undergone quality assurance by
University of North Carolina with 80–85% concordance of results
[10,11].
Discrepant results between cytology and histology resulted in a
review of the Pap smear slide. If discrepancy was confirmed, then a
repeat colposcopic biopsy was conducted if clinically indicated.
For quality assurance (QA) of the VIA technique, the study
gynecologist with a medical officer trained in colposcopy reviewed
each digital picture and the initial VIA diagnosis of the nurse
within two weeks of the VIA procedure. Medical staff was blinded
to both the cytology and HPV results at the time of VIA
interpretation. If the quality assurance team could not agree on
interpretation of VIA results, the digital photos were sent to
Professor Parham (blinded to initial readings) for a final diagnosis.
HPV testing QA was done per recommendation of the manufac-
ture’s guidelines. The final VIA reading used in the analysis was
the reading done after review by the doctors at the QA meeting.
However calculations using the nurse interpretation for CIN 2+
are also presented.
Statistical Methods
As all women were not referred for cytology verification by
colposcopy, using only the histology results to estimate sensitivity
and specificity could lead to biased inference. To correct for this
verification bias, we employed the maximum likelihood method
proposed by Zhou et al. [12]. Estimates using this method are
valid provided that the histology data are missing at random. This
assumption means that for women with the same test results, those
who were referred to colposcopy were similar to those that were
not. Corrected sensitivities and specificities of Pap, HPV DNA,
and VIA were estimated using maximum likelihood estimators
(MLEs). The positive predictive values (PPVs) and the negative
predictive values (NPVs) were also calculated accordingly. 95%
confidence intervals (CI) of sensitivities, specificities, PPVs and
NPVs were derived based on the asymptotic normality of the
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MLEs and their asymptotic variances that were estimated by the
inverse Fisher information.
For estimation of sensitivity and specificity for CIN-2+ or CIN-
3+, Pap smear results were considered negative if the test result
was negative, LSIL or ASCUS, and positive if the result was HSIL,
ASC-H, or SCC. However additional sensitivity and specificity
analyses were done evaluating the Pap smear results comparing
negative to positive if the results were ASCUS, LSIL, HSIL, ASC-
H or SCC. Estimated sensitivities and specificities of the screening
tests, stratified by levels of CD4 counts (#200 cells/mm3, 201–350
cells/mm3, 351–500 cells/mm3 and .500 cells/mm3), HIV viral
load #400 copies/ml, 401–1000 copies/ml and .1000 copies/ml)
and combination antiretroviral therapy (cART) (yes and no), were
compared across categories using the standard Z test, assuming
independent samples. Agreement between the VIA results by
gynecologists and by nurses was measured by a kappa statistic No
adjustment was made for multiple comparisons. All statistical
analyses were conducted using SAS 9.2 (Cary, North Carolina,
USA). The Analysis of VIA for determining CIN 2+ was evaluated
by looking at the gynecologists and the nurses VIA interpretation
separately.
Results
Participant Demographics and Overall Screening Results
A total of 1,202 women were screened between November 2009
and August 2011. Of these, 9 were excluded (6 had inadequate or
no cytology; 3 had invalid HPV or VIA results). A total of 1,193
women (98.1% black African) were evaluated, with a median age
of 38 years (IQR 32–43) and a median CD4 count of 394 cells/
mm3 (Interquartile range [IQR] 252.5–572). Approximately 75%
(N = 872) of our population had abnormal Pap smears, of which a
third (N = 399) of the overall the Pap smears results were high
grade lesion by cytology. VIA and HPV were positive in 45%
(N = 528) and 61% (N = 727) of participating women, respectively.
There were two diagnosed cases of invasive cervical carcinoma. Of
the 93.1% (N = 1111) women on cART, 82.9% had undetectable
HIV viral loads (#400 copies/ml).
Figure 1 shows the study flow-chart. Confirmative colposcopy
and biopsy was obtained on 94.4% of the study participants with
abnormal Pap smear or VIA test results (878/930). The most
common reasons for not obtaining a colposcopic biopsy [5.6%
(N = 52)] were lost to follow up (N = 19) and pregnancy (N = 11).
Approximately 25% (N = 63) of all negative VIA and Pap smear
cases also received verification colposcopic biopsies to adjust for
verification bias. Table 1 shows the HPV/VIA results stratified by
cytology and biopsy results.
As stand-alone tests, overall sensitivity for the detection of CIN-
2+ was the highest for HPV testing (92%), followed by Pap smears
(76%) and VIA at 65.4% (nurse interpretation)). However VIA
sensitivity was increase to 76% with physician QA review.
Specificity for CIN-2+ was the highest for Pap smears (83%),
followed by VIA (68% for both doctor and nurse interpretation),
and lowest for HPV testing (51%). When CIN3+ was used as the
end point, sensitivities were higher, while specificities somewhat
lower (,10%) than observed for CIN-2. Pap smears had a notably
higher sensitivity (95%) for CIN-3+ with a corresponding decrease
in specificity (73%). Sensitivity for the detection of CIN-3+
increased by 0.7% for VIA, 6.0% for HPV, and 18.7% for
cytology as compared to CIN-2+ (Table 2).
When the results of two screening methods were combined as
either test positive, the sensitivity increased to above 89% for
detecting CIN 2+ and greater than 97% for CIN 3+. However,
there was a corresponding decrease in specificity (Table 2). For
CIN2+, the HPV/VIA combination achieved the highest sensi-
tivity (95.6%), but also the lowest specificity (42.4%); the Pap
smear/VIA combination had the highest specificity (60.4%). For
CIN3+, all combined tests exhibited high sensitivity (.97%); the
highest specificity was achieved by the Pap smear/VIA combina-
tion (50.7%). When both tests were required to be positive (i.e.
HPV and VIA both positive) specificity increased and sensitivity
declined compared to a single test (Table 2). Table 3 describes the
sensitivity and specificity for the tests when sequentially evaluating
the results after one positive test and then adding a second test.
Interestingly the most effective testing sequential strategy for
detecting CIN 2+ is performing HPV testing after a positive Pap
smear. The most specific test was performing a Pap smear after a
VIA. Positive and negative predictive value for the three screening
methods for both CIN 2+ and CIN 3+ are described in Table 4.
Screening results stratified by HIV disease status
We compared the operating characteristics of the three
screening methods by immune status of the patients using CD4
counts. Standard Z tests comparing the sensitivities and specific-
ities across strata of CD4 counts show that there was no significant
difference in sensitivities within different levels of CD4 counts.
However, specificity appeared significantly lower for women with
CD4 counts #200 cells/mm3 compared to CD4 counts .350
cells/mm3 (p,0.001 for HPV, p,0.001 for cytology, p = 0.002 for
VIA) (Table 5). Comparing the test performance characteristics
between women with HIV viral load #1000 and .1000 copies/
ml, or by cART status was not conducted due to the small
proportion of women who were not on cART (6.9%) and because
the vast majority had suppressed HIV viral loads.
Quality Assurance
14% of all participants had a discrepancy between cytology and
histology results. Verification biopsies were done on 25% of all
women with negative VIA and Pap smears. Only 3% (2/63) of
these verification histology results were positive, resulting in two
CIN 2 cases. Histological review of the follow-up Loop Electrical
Excision Procedure (LEEP) results for these two CIN-2 cases
revealed only minimal changes consistent with HPV infection. No
neoplasia was found. There was substantial agreement between
the VIA readings of the nurse and that of the doctor [kappa
statistic = 0.69 (95% CI 0.64–0.73)].
Discussion
This analysis of just over 1,200 HIV-infected women represents,
to our knowledge, the largest comparative screening study of HIV-
infected women, comparing the screening performance of three
cervical cancer screening methods to detect histological CIN 2+
endpoints. We observed a notably high rate of positive test results,
including 33% HSIL, 61% HPV DNA positivity, and 45% VIA
positivity. All three screening methods had sensitivities of .65%
for determining CIN 2+ disease in HIV positive women, with
variations in specificity for CIN-2 ranging from 83% for cytology
to 51% for HPV testing. Test sensitivities were similar across strata
of CD4 counts, while the specificities of all the screening methods
decreased with immune suppression as measured by CD4 counts.
The observed HSIL prevalence in this study (33%) is almost
double than that previously reported from a different cohort of
1010 HIV-infected women from the same clinic (18%) [11]. The
vast majorities of study participants on this study were on cART
and were not significantly immunosuppressed. However, these
women had initiated cART when their CD4 counts were below
200cells/mm3, as per the South African HIV treatment guidelines
Cervical Cancer Screening in HIV+ Women
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and thus had a prior history of significant immunosuppression
[13]. Our higher observed prevalence of HSIL may be attributable
to women living longer due to cART use. These cytology results
expose the burden of high grade cervical dysplasia, and highlight
the significant public health problem of cervical dysplasia in HIV-
infected women in South Africa.
Figure 1. Study Flow Chart.
doi:10.1371/journal.pone.0053494.g001
Table 1. HPV/VIA results stratified by cytology and colposcopy results among 1193 women with a valid HPV test, VIA test and
cytology.
Cytology Colpo not done Negative CIN1 CIN2 CIN3 ICC Total
N (VIA+, HPV+) N (VIA+, HPV+) N (VIA+, HPV+) N (VIA+, HPV+) N (VIA+, HPV+) N (VIA+, HPV+) N (VIA+%, HPV+ %)
Negative (N = 321) 207 (7 ,50) 53 (17 ,19) 55 (30 ,22) 6 (4 ,3) 0 (0 ,0) 0 (0 ,0) 321 (18.1%, 29.3%)
ASCUS (N = 31) 2 (0 ,1) 3 (0 ,1) 24 (5 ,5) 2 (0 ,2) 0 (0 ,0) 0 (0 ,0) 31 (16.1%, 29.0%)
LSIL (N = 442) 21 (8 ,13) 24 (5 ,9) 338 (127 ,187) 54 (36 ,44) 5 (3 ,5) 0 (0 ,0) 442 (40.5%, 58.4%)
ASC-H (N = 30) 3 (2 ,1) 2 (0 ,0) 18 (3 ,9) 4 (2 ,4) 3 (1 ,3) 0 (0 ,0) 30 (26.7%, 56.7%)
HSIL (N = 367) 19 (15 ,18) 4 (1 ,3) 109 (67 ,98) 142 (121 ,137) 91 (71 ,89) 2 (2 ,2) 367 (75.5%, 94.6%)
SCC (N = 2) 0 (0 ,0) 0 (0 ,0) 1 (0 ,1) 0 (0 ,0) 1 (1 ,1) 0 (0 ,0) 2 (50.0%, 100.0%)
Total (N = 1193) 252 (32 ,83) 86 (23 ,32) 545 (232 ,322) 208(163,190) 100 (76,98) 2 (2 ,2) 1193 (44.3%, 60.9%)
Cytology = Cytology Pap smear, HPV = HPV DNA, VIA = Visual inspection with 5% acetic acid, LSIL = Low grade squamous intra-epithelial lesions, ASCUS = Atypical
squamous cells of underdetermined significance, HSIL = High grade squamous intra-epithelial lesions, ASC-H = Atypical squamous cells cannot excluded high grade
lesion, SCC = Squamous cell carcinoma, CIN1 = Cervical intraepithelial neoplasia grade 1, CIN2 = Cervical intraepithelial neoplasia grade 2, CIN3 = Cervical intraepithelial
neoplasia grade 3, ICC = Invasive cervical cancer.
doi:10.1371/journal.pone.0053494.t001
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Cytology based screening (via the Pap smear) is the only
screening method that has been shown to reduce mortality in
many places in the world including middle and lower resource
countries such a Colombia, Chile and Vietnam [14–16]. The
performance of Pap smear screening for CIN 2+ among women in
general population-based studies internationally has ranges for
both sensitivity (40–86%) and specificity (88–99%) [17–19]. Our
study results were within these ranges.
At present, there are only three studies evaluating different
screening methods for the detection of histological CIN 2+ in HIV
infected women in Africa. None of these studies conducted had
direct comparisons of these three screening methods. In Nigeria
(N = 205), VIA was found to have a sensitivity and specificity of
76% (95% CI 52–91%) and 83% (95% CI 77.0–88.0%),
respectively [3]. In Kenya, VIA was performed in 150 HIV
infected women and was found to have a sensitivity 69.6% (CI
55.1–81%) and specificity of 51% (CI 41.5–60.4%) [4]. A total of
956 HIV infected women in Cape Town were studied, with an
observed sensitivity of VIA of 64% and HPV of 94% for detecting
CIN2+. Cytology was not evaluated in this study [5] The range of
average age of HIV infected women in these studies was somewhat
similar to ours from 34 years (Kenya, Nigeria) to 40 years in the
Cape Town cohort.
A very similar study to ours was performed with 303 HIV
positive women in India, and showed similar sensitivity/specificity
of VIA for CIN-2+ detection of 80/82% respectively [20]. This
Indian study showed a similar relationship between CD4 count
and specificity of the screening tests to our study. Women with
lower CD4 counts (,350 cells/mm3) had lower specificity for VIA
and cytology [20]. Overall, the sensitivity of VIA for CIN-2+
detection in HIV infected women within the five studies (including
our present study) has ranged from 64–80% and the specificity
from 76–83% [3–5,20].
The results of VIA in HIV negative women in two large meta-
analyses showed that the range of sensitivity of VIA was relatively
similar at 79%–80%. The range for specificity for VIA was slightly
higher (85–92%) in HIV-negative than in HIV infected women
[21,22].
The VIA sensitivity for CIN 2+ is within the range of the Pap
smear sensitivity in this study, although the observed specificity is
Table 2. Screening test performance: estimated sensitivity and specificity.
CIN2+ (N = 310)1 CIN3+ (N = 102)1
Sensitivity 95% CI Specificity 95% CI Sensitivity 95% CI Specificity 95% CI
Cytology* 75.8% (70.8–80.8) 83.4% (80.9–85.9) 94.5% (89.8–99.2) 72.7% (70.0–75.3)
VIA (doctor interpretation) 75.5% (70.5–80.4) 68.1% (65.0–71.3) 76.2% (67.9–84.5) 58.9% (56.0–61.9)
HPV 91.9% (88.5–95.3) 51.4% (48.0–54.8) 97.9% (95.0–100) 42.8% (39.8–45.7)
Cytology** 94.8% (90.5–99.2) 35.6% (32.2–38.9) 99.9% (98.8–100) 29.6% (26.9–32.3)
VIA (nurse interpretation) 65.4% (59.7–71.1) 68.5% (65.3–71.7) 68.2% (59.3–77.2) 61.5% (58.6–64.4)
Combined (Or)** Cytology or VIA 89.3% (85.4–93.3) 60.4% (57.1–63.8) 97.4% (93.9–100) 50.7% (47.7–53.6)
Combined (Or)** Cytology or HPV 94.3% (91.3–97.4) 48.5% (45.1–51.9) 99.9% (99.4–100) 39.9% (37.0–42.9)
Combined (Or)** HPV or VIA 95.6% (92.8–98.4) 42.4% (39.1–45.8) 99.0% (97.0–100) 34.7% (31.8–37.5)
Combined (Or)** Cytology or VIA or HPV 96.4% (93.8–99.0) 40.8% (37.4–44.2) 99.9% (99.4–100) 32.9% (30.1–35.8)
Combined (And)** Cytology & VIA 61.3% (55.8–66.8) 91.1% (89.1–93.0) 72.8% (64.1–81.5) 80.9% (78.6–83.3)
Combined (And)** Cytology & HPV 72.6% (67.4–77.8) 86.2% (83.9–88.6) 91.8% (85.9–97.6) 75.5% (72.9–78.1)
Combined (And)** HPV & VIA 71.0% (65.8–76.2) 77.0% (74.1–79.9) 74.6% (66.0–83.1) 67.0% (64.2–69.8)
Combined (And)** Cytology & VIA & HPV 59.3% (53.8–64.8) 91.6% (89.7–93.5) 71.5% (62.6–80.4) 81.8% (79.5–84.2)
194.4% (878/930) of women with abnormal Pap smear/VIA and 25% (63/272) women with negative VIA/Pap smear received a colposcopic biopsy.
CIN2+ = CIN2/CIN3/ICC, CIN3+ = CIN3/ICC, CI = Confidence interval, Cytology = Cytology Pap smear, HPV = HPV DNA, VIA = Visual inspection with 5% acetic acid.
*Cytology negative: normal/LSIL/ASCUS; positive: HSIL, ASC-H, SCC.
**Cytology negative: normal; positive: otherwise.
A combined test in ‘‘Combined (Or)’’ is positive if either/any of the tests is positive. A Combined test in ‘‘Combined (And)’’ is positive if both/all of the tests are positive.
doi:10.1371/journal.pone.0053494.t002
Table 3. Sequential screening tests.
CIN2+ CIN3+
Sensitivity 95% CI Specificity 95% CI Sensitivity 95% CI Specificity 95% CI
Cytology+ HPV 96.6% (94.4–98.9) 17.3% (11.0–23.6) 97.8% (94.9–100) 10.4% (6.90–13.9)
Cytology+ VIA 81.7% (77.0–86.5) 46.7% (38.4–55.1) 77.5% (69.3–85.8) 30.4% (25.1–35.6)
HPV+ Cytology 79.8% (75.1–84.5) 71.8% (67.4–76.2) 94.3% 89.5–99.1) 57.2% (53.3–61.1)
HPV+ VIA 78.1% (73.3–82.9) 53.0% (48.1–57.8) 76.7% (68.4–85.0) 42.4% (38.5–46.3)
VIA+ Cytology 81.9% (77.1–86.7) 72.2% (66.8–77.6) 96.1% (91.7–100) 53.6% (49.0–58.3)
VIA+ HPV 94.8% (92.0–97.6) 28.0% (22.6–33.3) 98.6% (95.9–100) 19.7% (16.0–23.4)
doi:10.1371/journal.pone.0053494.t003
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not as high as the Pap smear in HIV positive women. However for
reasons that are unclear, the Pap smear had a much higher
sensitivity then the VIA (which remained unchanged) for detecting
CIN 3+. Sequential HPV testing as seen in Table 3 improves this
senstitivity to 98.6%. However, VIA offers the advantage of being
relatively inexpensive to implement where access to cytology based
systems are not available, offers the possibility of same visit
treatment and can be performed by a nurse after a short training
period (often two weeks). An additional advantage of VIA is that
the nurse can immediate treat an appropriate lesion by
cryotherapy. This allows the woman to be screened and treated
in one clinic visit decreasing the risk of lost to follow up of these
high risk women and reduces the number of clinic visits for
overwhelmed and under-capacitated clinics [8].
High risk HPV DNA was present in 61% of participants in our
study which is somewhat higher than that observed among 956
HIV-infected women from Cape Town (46%) [5], yet consistent
with prevalence rates of oncogenic HPV among other HIV-
infected women worldwide [23]. HPV typing in our study was
sensitive for high-grade detection (92% for CIN-2+, 98% for CIN-
3+), although specificity was lower (51.1% for CIN-2, 42.8% for
CIN-3). HPV testing could be used in combination with either
VIA or Pap smear to increase specificity and possibly reduce
follow-up procedures such as colposcopy. Adding HPV testing
after a positive Pap smear or VIA increased the sensitivity of these
tests to the levels slightly for CIN 2+ above HPV testing alone but
the addition of HPV testing to VIA did improve the reduce
sensitivity of VIA for CIN 3+. However adding the HPV testing
significantly diminished the specificity of the Pap smear and VIA
screening tests alone. HPV testing offers the possibility of self-
testing with a relatively high sensitivity for CIN-2+ in HIV
negative women [24]. However, HPV testing is, at present,
relatively expensive and requires skilled laboratory services. A new
HPV test called Care-HPV (QIAGEN/PATH) which is less
expensive and simpler to perform will hopefully be available soon
for commercial use [25].
South Africa has one of the highest HIV prevalence rates in the
world [26]. As HIV infected women have improved access to
cART due to government and donor programs, women are living
relatively longer lives [27,28] and thus are at a higher risk of
progression from CIN 2/3 to invasive cervical carcinoma. In our
study the specificity of HPV, VIA and cytology, appeared to be
lower among women with lower CD4 counts, and the reason for
this observation is unclear. One speculation might be that in
women with lower CD4 counts there maybe have other infections
causing interference with the tests decreasing specificity. Under-
standing if and why immunosuppression would lead to lower test
specificity is intriguing and requires further evaluation. These
results need to be replicated, and further research is also needed
evaluating the effect of HIV disease status on screening. Given that
Table 4. Screening test performance: estimated corrected positive predictive value and negative predictive values.
CIN2+ (N = 310) CIN3+ (N = 102)
PPV 95% CI NPV 95% CI PPV 95% CI NPV 95% CI
Cytology* 64.5% (59.7–69.3) 89.7% (87.3–92.1) 25.7% (21.3–30.1) 99.2% (98.6–99.9)
VIA 48.5% (44.0–53.0) 87.5% (84.6–90.3) 15.7% (12.4–18.9) 96.1% (94.6–97.6)
HPV 42.9% (39.0–46.8) 94.1% (91.5–96.7) 14.6% (11.9–17.3) 99.5% (98.8–100)
Combined Cytology/VIA 47.3% (43.4–51.3) 93.4% (90.9–96.0) 16.6% (13.6–19.5) 99.5% (98.8–100)
Combined Cytology/HPV 42.2% (38.5–45.8) 95.5% (93.1–98.0) 14.3% (11.7–16.9) 100% (99.9–100)
Combined HPV/VIA 39.8% (36.3–43.3) 96.0% (93.4–98.6) 13.2% (10.8–15.6) 99.7% (99.1–100)
Combined Cytology/VIA/HPV 40.8% (37.3–44.3) 96.4% (93.7–99.0) 13.8% (11.3–16.2) 100% (99.8–100)
CIN2+ = CIN2/CIN3/ICC, CIN3+ = CIN3/ICC, PPV = Positive predictive value, NPV = Negative predictive value, CI = Confidence interval, Cytology = Cytology Pap smear,
HPV = HPV DNA, VIA = Visual inspection with 5% acetic acid.
*Cytology negative: normal/LSIL/ASCUS; positive: HSIL, ASC-H, SCC.
doi:10.1371/journal.pone.0053494.t004
Table 5. Screening test performance for CIN2+: estimated corrected sensitivity and specificity by CD4 count (cells/mm3).
CD4 CIN-2+ cases Sensitivity p value* Specificity p value*
Cytology** #200 58 74.0% (62.3–85.6) 74.3% (65.7–83.0)
201–350 103 82.1% (74.5–89.7) 0.086 81.7% (76.6–86.7) 0.033
.350 146 71.9% (64.3–79.5) 0.778 85.9% (82.8–88.9) ,0.001
HPV #200 58 92.7% (85.2–100) 31.6% (22.3–40.9)
201–350 103 97.4% (93.7–100) 0.038 41.7% (35.3–48.1) 0.024
.350 146 88.8% (83.3–94.4) 0.687 59.7% (55.4–64.0) ,0.001
VIA #200 58 72.5% (60.8–84.1) 60.6% (50.9–70.3)
201–350 103 83.3% (75.9–90.7) 0.032 64.0% (57.7–70.3) 0.25
.350 146 71.3% (63.7–78.9) 0.683 71.1% (67.2–75.1) 0.002
*This is the p value comparing each group with the reference group (#200 cells/mm3).
**Cytology negative: normal/LSIL/ASCUS; positive: HSIL, ASC-H, SCC.
doi:10.1371/journal.pone.0053494.t005
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cART has recently been shown to be potentially effective in
decreasing the rate of progression to HSIL or more severe [29–
31], randomized controlled trials will be required to examine the
effect of starting ART earlier on the incidence of HSIL lesions.
In terms of study strengths, we implemented intense QA
measures to ensure reliable visual inspection results, which
included weekly meetings to review all digital photos by a team
of study personnel. This helped ongoing education of the nursing
staff and likely contributed to the good correlation between the
nurses’ and doctors’ VIA readings. In addition to skills resources
needed, the QA of VIA also required significant infrastructure (i.e.
electricity, computers and projectors). Such resources may not be
available in other areas of South Africa or other RLC. However,
this QA model to optimize VIA results was adapted from the
program in Lusaka, Zambia. For rural sites in resource limited
countries, this essential QA model could potentially be modified by
sending pictures via ‘‘memory sticks’’/CDs or through cell phones
to skilled personnel. We have been able to achieve this model in
rural South Africa.
Study limitations relate to the study review and intense QA
which might be difficult to successfully replicate in other public
clinic and non-academic environments. Participant files were
reviewed to ensure results and follow-up visits were achieved. In
busy under-resourced clinics in RLC, these types of review and
meetings may be extremely difficult to thoroughly implement.
Further, most of our patients were on effective cART so
precluding our ability to determine the effect of cART and HIV
viral load on screening.
Cervical cancer screening in HIV positive women is an urgent
public health requirement which demands immediate attention
and coordinated efforts of both national and local governments.
Our study results indicate that all three screening modalities
(HPV, VIA, cytology) are viable alternatives for consideration as
screening options in different programmatic settings, which is
important as a ‘‘one size fits all approach’’ may not to work. The
decision of which screening modality to implement will be
influenced by cost, patient population, availability of skilled
human resource and laboratory capacity. Within this decision
process, quality assurance needs to be considered at all stages of
the program. Careful consideration and evaluation will be needed
to determine for the best screening approach for a country and
maybe for different geographical settings within a country.
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